BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON, ROCHE, NOVARTIS

Big Pharma Kicks Off Q2 Earnings Calls After More than 100 Price Hikes to Start July

This week, Roche, Novartis, and Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the second quarter of 2022. After drug companies raised prices on more than 100 brand-name pharmaceuticals in the first week of July, Big Pharma continues to surpass earnings expectations while growing sales and posting massive profits.

Johnson & Johnson

Roche

Novartis

The blockbuster earnings come as Big Pharma giants have hiked prices on hundreds of prescription drugs. July is typically the second busiest month for price hikes on prescription drugs and, as expected, brand name drug makers have hiked prices on 112 prescription drugs so far this month. The Big Pharma drug makers who reported second quarter earnings this week all share a history of hiking prices and engaging in egregious pricing practices.

Johnson & Johnson

Roche

Novartis

Stay tuned as we continue to monitor earnings calls from Big Pharma for Q2 of 2022 over the next few weeks.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.